Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake…
Conditions studied
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
About this study
Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.
Primary outcomes
- Baseline Urine Angiotensin-(1-7)/Creatinine Ratio (Baseline)
- Change in Urine Angiotensin-(1-7)/Creatinine Ratio (Baseline through 2 years)
- Baseline Urine Angiotensin II/Angiotensin-(1-7) Ratio (Baseline)
- Change in Urine Angiotensin II/Angiotensin-(1-7) Ratio (Baseline through 2 years)
- Baseline Plasma Angiotensin-(1-7) Level (Baseline)
- Change in Plasma Angiotensin-(1-7) Level (Baseline through 2 years)
- Baseline Plasma Angiotensin II/Angiotensin-(1-7) Ratio (Baseline)
- Change in Plasma Angiotensin II/Angiotensin-(1-7) Ratio (Baseline through 2 years)
Eligibility information
Study locations
- Wake Forest Health Sciences, Winston-Salem, North Carolina 27157 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.